Composition for suppressing alopecia or promoting hair restoration containing peptide

Abstract

To provide a composition for suppressing alopecia or promoting hair restoration containing a specific peptide.SOLUTION: A composition according to the present invention can effectively suppress alopecia or promote hair restoration by promoting or activating the growth or proliferation of hair papilla cells.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to a composition for inhibiting hair loss or promoting hair growth, which contains a specific peptide. [Background technology]

[0002] Human hair primarily serves a defensive function to protect the scalp from external stimuli such as ultraviolet rays, and also serves an aesthetic function to express an individual's external image. However, in modern society, hair loss is frequently occurring due to natural factors such as environmental pollution and strong ultraviolet rays, as well as physiological factors such as stress and hormonal imbalance. Unlike in the past, when hair loss was limited to adult men, it is now occurring in people of all ages and genders, and there is a strong demand for materials to prevent and treat hair loss.

[0003] Hair follicles, physiological organs in the body that produce hair, generate hair during postnatal development and undergo a hair growth cycle that is divided into the anagen phase, in which the generated hair actively grows; the catagen phase, in which the hair degenerates; the telogen phase, in which the hair remains until it falls out; and the exogen phase, in which hair loss occurs. Numerous studies have shown that the activity of hair follicles is driven by hair dermal papilla cells, and that the proliferation and differentiation of dermal papilla cells in particular are primarily involved in the progression of the hair growth cycle and hair formation. During the anagen phase, in which hair actively grows, dermal papilla cells actively proliferate and differentiate, whereas during the catagen, telogen, and exogen phases, in which hair growth ceases and hair loss occurs, these cells die. Therefore, since hair growth and hair loss are closely related to the proliferation and death of hair papilla cells, methods for improving and treating hair loss include lengthening the anagen phase by inducing proliferation, or shortening the catagen, telogen, and shedding phases by suppressing cell death.

[0004] Alopecia is a condition characterized by the loss of more than 100 hairs per day, a decrease in hair in the anagen phase, and an increase in hair in the catagen or telogen phase. As hair loss progresses, the proportion of hair in the telogen phase increases rapidly, while the proportion of hair in the anagen phase decreases. Hair loss is generally classified as hereditary androgenetic alopecia (baldness), alopecia areata, fungal infection-induced tinea capitis, telogen effluvium, trichotillomania, and hair production disorders. Among these, the most common types of hair loss include male-pattern hair loss (MAH), female-pattern hair loss (FPH), alopecia areata, and telogen effluvium. There are various causes of hair loss. Genetic factors and the male hormone androgen are thought to be important factors in the development of baldness. Female-pattern hair loss is thought to occur in part through the same pathway as male-pattern hair loss, although clinical manifestations differ. Alopecia areata is thought to be caused by an autoimmune disease. Telogen effluvium is a temporary hair loss that occurs after severe physical or mental stress such as endocrine disorders, nutritional deficiencies, drugs, childbirth, fever, or surgery, and occurs when some hairs transition to the resting phase before the growth period is complete and fall out. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Korean Patent Publication No. 10-2023-0047688 Summary of the Invention [Problem to be solved by the invention]

[0006] An object of the present invention is to provide a composition that exhibits excellent hair loss suppression or hair growth promotion effects by promoting or activating the growth or proliferation of hair papilla cells. [Means for solving the problem]

[0007] To achieve the above object, one embodiment of the present invention provides a composition for inhibiting hair loss or promoting hair growth, which comprises, as an active ingredient, a peptide having the amino acid sequence Gly-Pro-Lys (GPK), the amino acid sequence Gly-Pro-Ser (GPS), the amino acid sequence Gly-Pro-Ala (GPA), the amino acid sequence Gly-Gln-Lys (GQK), or the amino acid sequence Pro-Hyp (PO), or a salt thereof. [Effects of the Invention]

[0008] The composition according to the present invention can effectively inhibit hair loss or promote hair growth by promoting or activating the growth or proliferation of hair papilla cells. [Brief explanation of the drawings]

[0009] [Figure 1] FIG. 1 shows the results of confirming the effect of a GPK peptide in activating the proliferation of dermal papilla cells (relative dermal papilla cell proliferation (%)). [Figure 2] FIG. 1 shows the results of confirming the effect of GPS peptide in activating dermal papilla cell proliferation (relative dermal papilla cell proliferation (%)). [Figure 3] FIG. 1 shows the results of confirming the effect of GPA peptides on activating dermal papilla cell proliferation (relative dermal papilla cell proliferation (%)). [Figure 4] FIG. 1 shows the results of confirming the effect of GQK peptide in activating proliferation of dermal papilla cells (cell viability (% compared to the control group)). [Figure 5] FIG. 1 shows the results of confirming the effect of PO peptides on activating dermal papilla cell proliferation (relative dermal papilla cell proliferation (%)). DETAILED DESCRIPTION OF THE INVENTION

[0010] The present invention will be described in detail below.

[0011] One aspect of the present invention relates to a composition for inhibiting hair loss or promoting hair growth, which comprises, as an active ingredient, a peptide comprising the amino acid sequence Gly-Pro-Lys (GPK) or a salt thereof.

[0012] One aspect of the present invention relates to a composition for inhibiting hair loss or promoting hair growth, which comprises, as an active ingredient, a peptide comprising the amino acid sequence Gly-Pro-Ser (GPS) or a salt thereof.

[0013] One aspect of the present invention relates to a composition for inhibiting hair loss or promoting hair growth, which comprises, as an active ingredient, a peptide comprising the amino acid sequence Gly-Pro-Ala (GPA) or a salt thereof.

[0014] One aspect of the present invention relates to a composition for inhibiting hair loss or promoting hair growth, which comprises, as an active ingredient, a peptide comprising the amino acid sequence Gly-Gln-Lys (GQK) or a salt thereof.

[0015] One aspect of the present invention relates to a composition for inhibiting hair loss or promoting hair growth, which comprises, as an active ingredient, a peptide comprising the amino acid sequence (PO) of Pro-Hyp, or a salt thereof. One aspect of the present invention relates to a composition for inhibiting hair loss or promoting hair growth, which comprises, as an active ingredient, a peptide comprising the amino acid sequence Gly-Pro-Thr (GPT) or a salt thereof.

[0016] One aspect of the present invention relates to a composition for inhibiting hair loss or promoting hair growth, which comprises, as an active ingredient, a peptide comprising the amino acid sequence Arg-Lys (RK) or a salt thereof.

[0017] One aspect of the present invention relates to a composition for inhibiting hair loss or promoting hair growth, which comprises, as an active ingredient, a peptide comprising the amino acid sequence Pro-Gly-Glu (PGE) or a salt thereof.

[0018] The amino acids referred to herein by abbreviations are written according to the IUPAC-IUB nomenclature as follows: Glycine: G, Proline: P, Lysine: K, Serine: S, Alanine: A, Glutamine: Q, Hydroxyproline: O, Threonine: T, Arginine: R, Glutamic Acid: E

[0019] In one embodiment, the peptide contains at least 50%, at least 60%, at least 70%, at least 80% or at least 90%, preferably at least 95%, and most preferably 100% of the GPK, GPS, GPA, GQK, PO, GPT, RK or PGE amino acids.

[0020] In one embodiment, the peptide may be a GPK, GPS, GPA, GQK, PO, GPT, RK, or PGE peptide, i.e., the peptide may be a peptide consisting of the amino acid sequence Gly-Pro-Lys, Gly-Pro-Ser, Gly-Pro-Ala, Gly-Gln-Lys, Pro-Hyp, Gly-Pro-Thr, Arg-Lys, or Pro-Gly-Glu.

[0021] Although the present specification refers to a "peptide consisting of a specific amino acid sequence," this does not exclude meaningless additions to the amino acid sequence, naturally occurring mutations, or silent mutations thereof, as long as the peptide has the same or corresponding activity as the peptide consisting of the amino acid sequence. It goes without saying that those having such additions or mutations are also included in the present invention.

[0022] In one embodiment, the peptides can be produced by chemical synthesis methods known in the art, standard synthetic methods, enzymatic, base or acid proteolytic methods, or any other method known in the art.

[0023] The "peptide salt" herein may be a pharmaceutically or cosmetically acceptable salt. Specifically, the peptide salt may be formed by adding an acid to the peptide, for example, an inorganic acid (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, etc.), an organic carboxylic acid (e.g., acetic acid, haloacetic acid such as trifluoroacetic acid, propionic acid, maleic acid, succinic acid, malic acid, citric acid, tartaric acid, salicylic acid), an acidic sugar (glucuronic acid, galacturonic acid, gluconic acid, ascorbic acid), an acidic polysaccharide (e.g., hyaluronic acid, chondroitin sulfate, alginic acid), an organic sulfonic acid (e.g., methanesulfonic acid, p-toluenesulfonic acid) including a sulfonic acid sugar ester such as chondroitin sulfate, etc.

[0024] In one embodiment, the peptide or its salt may be contained in the composition at a concentration of 0.001 to 200 μM.

[0025] For example, the concentration of the peptide or its salt in the composition is 0.001 μM or more, 0.005 μM or more, 0.01 μM or more, 0.05 μM or more, 0.1 μM or more, 0.5 μM or more, 1 μM or more, 5 μM or more, 10 μM or more, 15 μM or more, 20 μM or more, 25 μM or more, 30 μM or more, 35 μM or more, 40 μM or more, 45 μM or more, 50 μM or more, M or more, 55 μM or more, 60 μM or more, 65 μM or more, 70 μM or more, 75 μM or more, 80 μM or more, 85 μM or more, 90 μM or more, 95 μM or more, 100 μM or more, 110 μM or more, 120 μM or more, 130 μM or more, 140 μM or more, 150 μM or more, 160 μM or more, 170 μM or more, 180 μM or more, or 190 μM or more. Furthermore, the concentration of the peptide or its salt in the composition is 200 μM or less, 190 μM or less, 180 μM or less, 170 μM or less, 160 μM or less, 150 μM or less, 140 μM or less, 130 μM or less, 120 μM or less, 110 μM or less, 100 μM or less, 95 μM or less, 90 μM or less, 85 μM or less, 80 μM or less, 75 μM or less, 70 μM or less, μM or less, 65 μM or less, 60 μM or less, 55 μM or less, 50 μM or less, 45 μM or less, 40 μM or less, 35 μM or less, 30 μM or less, 25 μM or less, 20 μM or less, 15 μM or less, 10 μM or less, 5 μM or less, 1 μM or less, 0.5 μM or less, 0.1 μM or less, 0.05 μM or less, 0.01 μM or less, or 0.005 μM or less.

[0026] In one embodiment, the peptide or its salt may be used to treat cells at a concentration of 0.1 to 10 μM.

[0027] For example, cells may be treated with the peptide or its salt at a concentration of 0.1 μM or more, 0.2 μM or more, 0.3 μM or more, 0.4 μM or more, 0.5 μM or more, 0.6 μM or more, 0.7 μM or more, 0.8 μM or more, 0.9 μM or more, 1 μM or more, 2 μM or more, 3 μM or more, 4 μM or more, 5 μM or more, 6 μM or more, 7 μM or more, 8 μM or more, or 9 μM or more; or cells may be treated with the peptide or its salt at a concentration of 10 μM or less, 9 μM or less, 8 μM or less, 7 μM or less, 6 μM or less, 5 μM or less, 4 μM or less, 3 μM or less, 2 μM or less, 1 μM or less, 0.9 μM or less, 0.8 μM or less, 0.7 μM or less, 0.6 μM or less, 0.5 μM or less, 0.4 μM or less, 0.3 μM or less, or 0.2 μM or less.

[0028] In one embodiment, the cells may be dermal papilla cells.

[0029] In one embodiment, the peptide or salt thereof may promote or activate the growth or proliferation of dermal papilla cells.

[0030] In one embodiment, the composition may be a pharmaceutical composition for preventing or treating hair loss.

[0031] As used herein, "prevention" means reducing the risk of developing a disease or disorder, and refers to any action that prevents the development of at least one clinical symptom of the disease, inhibits or delays the onset of the disease in a subject who is susceptible to being exposed to or developing the disease, but who is not yet diseased or symptomatic of the disease.

[0032] As used herein, "treatment" means alleviating a disease or disorder and includes any action that improves or beneficially alters the symptoms of a disease by arresting or reducing the progression of the disease or at least one clinical symptom thereof.

[0033] In one embodiment, the daily dose of the peptide or its salt may be 0.0002 to 100 mg / kg (body weight). Specifically, the daily dose of the peptide or its salt may be 0.0002 mg / kg (body weight) or more, 0.0003 mg / kg (body weight) or more, 0.0005 mg / kg (body weight) or more, 0.0007 mg / kg (body weight) or more, 0.001 mg / kg (body weight) or more, 0.005 mg / kg (body weight) or more, 0.01 mg / kg (body weight) or more, 0.03 mg / kg (body weight) or more, 0.05 mg / kg (body weight) or more, 0.07 mg / kg (body weight) or more, 0.08 mg / kg (body weight) or more, 0.1 mg / kg (body weight) or more. g (body weight) or more, 0.5 mg / kg (body weight) or more, 1 mg / kg (body weight) or more, 5 mg / kg (body weight) or more, 10 mg / kg (body weight) or more, 15 mg / kg (body weight) or more, 20 mg / kg (body weight) or more, 25 mg / kg (body weight) or more, 30 mg / kg (body weight) or more, 35 mg / kg (body weight) or more, 40 mg / kg (body weight) or more, 45 mg / kg (body weight) or more, 50 mg / kg (body weight) or more, 60 mg / kg (body weight) or more, 70 mg / kg (body weight) or more, 80 mg / kg (body weight) or more or 9 The daily dose of the peptide or salt thereof may be 100 mg / kg (body weight) or less, 90 mg / kg (body weight) or less, 80 mg / kg (body weight) or less, 60 mg / kg (body weight) or less, 50 mg / kg (body weight) or less, 45 mg / kg (body weight) or less, 40 mg / kg (body weight) or less, 35 mg / kg (body weight) or less, 30 mg / kg (body weight) or less, 25 mg / kg (body weight) or less, 20 mg / kg (body weight) or less, 15 mg / kg (body weight) or less, 10 mg / kg (body weight) or less, The dose may be 0.07mg / kg (body weight) or less, 5mg / kg (body weight) or less, 1mg / kg (body weight) or less, 0.9mg / kg (body weight) or less, 0.5mg / kg (body weight) or less, 0.1mg / kg (body weight) or less, 0.07mg / kg (body weight) or less, 0.05mg / kg (body weight) or less, 0.03mg / kg (body weight) or less, 0.01mg / kg (body weight) or less, 0.005mg / kg (body weight) or less, 0.001mg / kg (body weight) or less, 0.0007mg / kg (body weight) or less, or 0.0005mg / kg (body weight) or less.

[0034] In one embodiment, the peptide or its salt may be contained in the pharmaceutical composition in a therapeutically effective amount, and may further include a pharmaceutically acceptable carrier. The "therapeutically effective amount" refers to an amount sufficient to achieve the purpose of the composition, which is to prevent or treat hair loss.

[0035] As used herein, hair loss refers to the absence of hair in areas where hair should normally be present, and includes a phenomenon in which the number of hairs is reduced compared to normal.The concept of hair loss includes both non-cicatricial hair loss and cicatricial hair loss depending on whether hair follicles are destroyed or not, and includes, for example, hereditary androgenetic alopecia, alopecia areata, tinea capitis due to fungal infection, telogen effluvium, trichotillomania, hair production disorder, hair loss due to lupus, folliculitis barbae, lichen planus pilaris, and hair loss due to burns and / or trauma.

[0036] The prevention or treatment of hair loss may involve removing the cause of the hair loss, inhibiting the progression of hair loss, inhibiting hair loss, or promoting hair formation to promote hair growth.

[0037] In one embodiment, the pharmaceutical composition may be prepared in unit dose form or in multi-dose containers by formulating it with pharmaceutically acceptable carriers and / or excipients according to a method readily understood by those skilled in the art, wherein the formulation may be in the form of a solution, suspension, or emulsion in an oily or aqueous medium, or in the form of an extract, powder, granules, tablets, capsules, or gel (e.g., hydrogel), and may further include a dispersing agent or stabilizer.

[0038] In one embodiment, the peptide or salt thereof contained in the pharmaceutical composition may be delivered by a pharmaceutically acceptable carrier such as a colloidal suspension, a powder, saline, lipids, liposomes, microspheres, nano-spherical particles, etc. These may be complexed or associated with a delivery vehicle, and may be delivered in vivo by delivery systems known in the art, such as lipids, liposomes, microparticles, gold nanoparticles, polymers, condensation reagents, polysaccharides, polyamino acids, dendrimers, saponins, adsorption promoters, fatty acids, etc.

[0039] Other pharmaceutically acceptable carriers include, but are not limited to, those commonly used in formulations, such as lactose, glucose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, etc. In addition to the above ingredients, the formulation may further contain lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc.

[0040] In one embodiment, the pharmaceutical composition may be administered orally or parenterally and may be used in the form of a common pharmaceutical formulation. That is, the pharmaceutical composition of the present invention can be administered in a variety of oral and parenteral formulations, which are typically prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Oral solid formulations include tablets, pills, powders, granules, capsules, and the like. These solid formulations are prepared by mixing herbal extracts or fermented herbal products with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, or gelatin. In addition to the usual excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid formulations include suspensions, oral solutions, emulsions, syrups, and the like. In addition to the commonly used diluents such as water and liquid paraffin, various excipients, such as wetting agents, sweeteners, flavorings, and preservatives, are used. Parenteral formulations include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases include witepsol, macrogol, Tween 61, cocoa butter, laurin butter, glycerol, and gelatin.

[0041] In one embodiment, the pharmaceutical composition may be a topical skin preparation. The topical skin preparation is a formulation applied to the outside of the skin. When the pharmaceutical composition of the present invention is used as a topical skin preparation, it may be applied to the scalp, specifically to the scalp at a site of hair loss or to a site where hair growth is desired to be promoted. The topical skin preparation may be a cream, gel, ointment, emollient, skin suspension, transdermal patch, drug-containing bandage, lotion, or a combination thereof. The topical skin preparation may be appropriately blended with ingredients commonly used in topical skin preparations such as cosmetics and pharmaceuticals, for example, aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, UV absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, or combinations thereof, as needed. The topical skin preparation may be appropriately blended with chelating agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid; drugs such as caffeine, tannin, verapamil, licorice extract, glabridin, hot water extract of Chinese quince fruit, various herbal medicines, tocopherol acetate, glycyrrhizic acid, tranexamic acid, derivatives thereof, and salts thereof; vitamin C, magnesium ascorbyl phosphate, ascorbyl glucoside, arbutin, kojic acid, sugars such as glucose, fructose, and trehalose; and the like.

[0042] In one embodiment, the composition may be a cosmetic composition.

[0043] In one embodiment, the daily dosage of the peptide or its salt may be 0.0002 to 100 mg / kg (body weight). Specifically, the daily dosage of the peptide or its salt is 0.0002 mg / kg (body weight) or more, 0.0003 mg / kg (body weight) or more, 0.0005 mg / kg (body weight) or more, 0.0007 mg / kg (body weight) or more, 0.001 mg / kg (body weight) or more, 0.005 mg / kg (body weight) or more, 0.01 mg / kg (body weight) or more, 0.03 mg / kg (body weight) or more, 0.05 mg / kg (body weight) or more, 0.07 mg / kg (body weight) or more, 0.08 mg / kg (body weight) or more, 0.1 mg / kg (body weight) or more. g (body weight) or more, 0.5 mg / kg (body weight) or more, 1 mg / kg (body weight) or more, 5 mg / kg (body weight) or more, 10 mg / kg (body weight) or more, 15 mg / kg (body weight) or more, 20 mg / kg (body weight) or more, 25 mg / kg (body weight) or more, 30 mg / kg (body weight) or more, 35 mg / kg (body weight) or more, 40 mg / kg (body weight) or more, 45 mg / kg (body weight) or more, 50 mg / kg (body weight) or more, 60 mg / kg (body weight) or more, 70 mg / kg (body weight) or more, 80 mg / kg (body weight) or more or 9 The daily dose of the peptide or a salt thereof may be 100 mg / kg (body weight) or less, 90 mg / kg (body weight) or less, 80 mg / kg (body weight) or less, 60 mg / kg (body weight) or less, 50 mg / kg (body weight) or less, 45 mg / kg (body weight) or less, 40 mg / kg (body weight) or less, 35 mg / kg (body weight) or less, 30 mg / kg (body weight) or less, 25 mg / kg (body weight) or less, 20 mg / kg (body weight) or less, 15 mg / kg (body weight) or less, 10 mg / kg (body weight) or less, The dose may be 0.07mg / kg (body weight) or less, 5mg / kg (body weight) or less, 1mg / kg (body weight) or less, 0.9mg / kg (body weight) or less, 0.5mg / kg (body weight) or less, 0.1mg / kg (body weight) or less, 0.07mg / kg (body weight) or less, 0.05mg / kg (body weight) or less, 0.03mg / kg (body weight) or less, 0.01mg / kg (body weight) or less, 0.005mg / kg (body weight) or less, 0.001mg / kg (body weight) or less, 0.0007mg / kg (body weight) or less, or 0.0005mg / kg (body weight) or less.

[0044] In one embodiment, the cosmetic composition may contain the peptide or its salt in a cosmetically effective amount, and may also contain a cosmetically acceptable carrier. The cosmetically effective amount means an amount sufficient to achieve the aforementioned effects of preventing hair loss or promoting hair growth.

[0045] In one embodiment, the cosmetic composition may further contain other ingredients, characterized by having a synergistic effect on the activity of the peptide, provided that the ingredients do not affect the hair loss prevention or hair growth promotion activity of the peptide. For example, the cosmetic composition may contain adjuvants commonly used in the cosmetic or dermatological fields, such as fatty substances, organic solvents, solubilizers, thickeners, gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or non-ionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, moisturizing agents, essential oils, dyes, pigments, fragrances, hydrophilic or lipophilic active agents, lipid vesicles, or any other ingredients commonly used in cosmetics, in amounts commonly used in the cosmetic or dermatological fields.

[0046] In one embodiment, the cosmetic composition may be a hair tonic, hair conditioner, hair essence, hair lotion, hair nourishing lotion, hair shampoo, hair rinse, hair treatment, hair cream, hair nourishing cream, hair moisturizing cream, hair massage cream, hair wax, hair aerosol, hair pack, hair nourishing pack, hair soap, hair cleansing foam, hair oil, hair drying agent, hair preservative, hair dye, hair waving agent, hair bleach, hair gel, hair glaze, hair dressing, hair lacquer, hair moisturizer, hair mousse, hair spray, eyebrow hair growth agent, eyelash hair growth agent, or eyelash nourishing agent.

[0047] In one embodiment, the cosmetic composition may be formulated into any formulation commonly used in the art, such as, but not limited to, a solution, suspension, emulsion, paste, powder, gel, cream, lotion, soap, oil, spray, etc.

[0048] When the cosmetic composition is formulated as a paste, cream, or gel, animal oils, vegetable oils, waxes, paraffins, starches, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silica, talc, zinc oxide, and the like may be used as carrier components.

[0049] When the cosmetic composition is formulated as a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component, and particularly in the case of a spray, a propellant such as hydrochlorofluorocarbon, propane / butane, or dimethyl ether may further be included.

[0050] When the cosmetic composition is formulated as a solution or emulsion, a solvent, solubilizer, or emulsifier is used as a carrier component, such as water, ethanol, isopropanol, diethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerin aliphatic esters, polyethylene glycol, or sorbitan fatty acid esters.

[0051] When the cosmetic composition is prepared as a suspension, the carrier component may be a liquid diluent such as water, ethanol, or propylene glycol; a suspending agent such as ethoxylated stearyl alcohol, polyoxyethylene sorbitol ester, or polyoxyethylene sorbitan ester; or microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tragacanth.

[0052] In addition to the active ingredient and carrier component, the cosmetic composition may contain ingredients that are commonly used in topical skin preparation compositions, such as common adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances.

[0053] In one embodiment, the composition may be a food composition, a nutraceutical composition or a non-therapeutic oral composition.

[0054] In one embodiment, the daily intake of the peptide or its salt may be 0.0002 to 100 mg / kg (body weight). Specifically, the daily intake of the peptide or its salt may be 0.0002 mg / kg (body weight) or more, 0.0003 mg / kg (body weight) or more, 0.0005 mg / kg (body weight) or more, 0.0007 mg / kg (body weight) or more, 0.001 mg / kg (body weight) or more, 0.005 mg / kg (body weight) or more, 0.01 mg / kg (body weight) or more, 0.03 mg / kg (body weight) or more, 0.05 mg / kg (body weight) or more, 0.07 mg / kg (body weight) or more, 0.08 mg / kg (body weight) or more, 0.1 mg / kg (body weight) or more. (body weight) or more, 0.5mg / kg (body weight) or more, 1mg / kg (body weight) or more, 5mg / kg (body weight) or more, 10mg / kg (body weight) or more, 15mg / kg (body weight) or more, 20mg / kg (body weight) or more, 25mg / kg (body weight) or more, 30mg / kg (body weight) or more, 35mg / kg (body weight) or more, 40mg / kg (body weight) or more, 45mg / kg (body weight) or more, 50mg / kg (body weight) or more, 60mg / kg (body weight) or more, 70mg / kg (body weight) or more, 80mg / kg (body weight) or more or 90 The daily intake of the peptide or a salt thereof may be 100 mg / kg (body weight) or less, 90 mg / kg (body weight) or less, 80 mg / kg (body weight) or less, 60 mg / kg (body weight) or less, 50 mg / kg (body weight) or less, 45 mg / kg (body weight) or less, 40 mg / kg (body weight) or less, 35 mg / kg (body weight) or less, 30 mg / kg (body weight) or less, 25 mg / kg (body weight) or less, 20 mg / kg (body weight) or less, 15 mg / kg (body weight) or less, 10 mg / kg (body weight) or less. The concentration may be 0.07 mg / kg (body weight) or less, 5 mg / kg (body weight) or less, 1 mg / kg (body weight) or less, 0.5 mg / kg (body weight) or less, 0.1 mg / kg (body weight) or less, 0.09 mg / kg (body weight) or less, 0.07 mg / kg (body weight) or less, 0.05 mg / kg (body weight) or less, 0.03 mg / kg (body weight) or less, 0.01 mg / kg (body weight) or less, 0.005 mg / kg (body weight) or less, 0.001 mg / kg (body weight) or less, 0.0007 mg / kg (body weight) or less, or 0.0005 mg / kg (body weight) or less.

[0055] In one embodiment, the food composition or non-therapeutic oral composition is formulated into, but is not limited to, tablets, granules, pills, powders, liquids such as drinks, caramels, gels, bars, tea bags, etc. In addition to the active ingredient, the composition of each formulation can be formulated by a person skilled in the art by appropriately selecting and blending ingredients commonly used in the art according to the formulation or intended use, and when used simultaneously with other ingredients, a synergistic effect can be achieved.

[0056] In one embodiment, the food composition or non-therapeutic oral composition can be administered in a variety of ways, including by simple ingestion, drinking, injection, spraying, squeezing, etc.

[0057] In one embodiment, the food composition or non-therapeutic oral composition may be, for example, various foods such as chewing gum, chocolate, caramel products, candies, ice creams, confectioneries, etc.; beverages such as soft drinks, mineral water, alcoholic drinks, etc.; or functional foods containing vitamins, minerals, etc.

[0058] In one embodiment, the food composition or non-therapeutic oral composition may be ingested as is or may be used together with other foods or food ingredients in a conventional manner. The food composition or non-therapeutic oral composition may contain, in addition to the peptide or its salt, a food-safe food supplement additive, and the amount of active ingredient to be mixed is determined appropriately depending on the intended use.

[0059] In this specification, the term "supplementary food additive" refers to a component added to food as a supplement, which is added when producing functional foods of each formulation, and can be appropriately selected and used by those skilled in the art. Examples of supplementary food additives include various supplements, vitamins, minerals (electrolytes), flavorings such as synthetic flavorings and natural flavorings, colorants and fillers, pectinic acid and its salts, alginic acid and its salts, organic acids, protective colloids, thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, and carbonation agents used in carbonated beverages, but the types of supplementary food additives of the present invention are not limited to these examples.

[0060] As used herein, the term "functional food" refers to food manufactured and processed into the form of tablets, capsules, powders, granules, liquids, pills, etc. using raw materials or ingredients that have beneficial functions for the human body. Here, "functional" refers to regulating nutrients for the structure and function of the human body or providing beneficial effects for health purposes, such as physiological effects. The functional food of the present invention can be manufactured by methods commonly used in the art, and can be manufactured by adding raw materials and ingredients commonly added in the art. Furthermore, the functional food formulation may be any formulation recognized as a functional food. The food composition can be manufactured into various forms of formulations.

[0061] The present invention provides the following embodiment as an example.

[0062] The first embodiment provides a composition for inhibiting hair loss or promoting hair growth, which comprises, as an active ingredient, a peptide having the amino acid sequence Gly-Pro-Lys (GPK), the amino acid sequence Gly-Pro-Ser (GPS), the amino acid sequence Gly-Pro-Ala (GPA), the amino acid sequence Gly-Gln-Lys (GQK), or the amino acid sequence Pro-Hyp (PO), or a salt thereof.

[0063] A second embodiment provides a composition for inhibiting hair loss or promoting hair growth, wherein the peptide in the first embodiment is a GPK, GPS, GPA, GQK or PO peptide.

[0064] A third embodiment provides a composition for inhibiting hair loss or promoting hair growth, wherein the peptide or its salt is contained in the composition at a concentration of 0.1 to 100 μM in at least either the first embodiment or the second embodiment.

[0065] A fourth embodiment provides a composition according to at least any one of the first to third embodiments, wherein the peptide or its salt is used to treat cells at a concentration in the composition of 0.1 to 10 μM.

[0066] The fifth embodiment provides the composition according to at least any one of the first to fourth embodiments, wherein the cells are hair papilla cells.

[0067] The sixth embodiment provides a composition for inhibiting hair loss or promoting hair growth, wherein the peptide or a salt thereof promotes or activates the growth or proliferation of hair papilla cells in at least any of the first to fifth embodiments.

[0068] The seventh embodiment provides a composition for inhibiting hair loss or promoting hair growth, wherein the composition is a pharmaceutical composition for preventing or treating hair loss in at least any of the first to sixth embodiments.

[0069] The eighth embodiment provides a composition for inhibiting hair loss or promoting hair growth, wherein the daily dose of the peptide or its salt is 0.0003 to 30 mg / kg (body weight) in at least any one of the first to seventh embodiments.

[0070] The ninth embodiment provides a composition for inhibiting hair loss or promoting hair growth, wherein the composition is a cosmetic composition in at least any one of the first to eighth embodiments.

[0071] The tenth embodiment provides a composition for inhibiting hair loss or promoting hair growth, wherein the daily application amount of the peptide or a salt thereof is 0.0003 to 30 mg / kg (body weight) in at least any one of the first to ninth embodiments.

[0072] An eleventh embodiment provides a composition for inhibiting hair loss or promoting hair growth in at least any one of the first to tenth embodiments, wherein the composition is a food composition.

[0073] The 12th embodiment provides a composition for inhibiting hair loss or promoting hair growth, wherein the daily intake of the peptide or a salt thereof is 0.0003 to 30 mg / kg (body weight) in at least any one of the 1st to 11th embodiments.

[0074] The present invention will be described in more detail below with reference to examples. However, these examples are merely provided for the purpose of understanding the present invention, and the present invention is not limited to these examples. Modifications, substitutions, insertions, etc. well known in the art may be made, and these are also included in the present invention.

[0075] [Example] Confirmation of the effect of activating hair papilla cell proliferation Human dermal papilla cells (HDPCs) were attached to 96-well plates at 2,000 cells per well and cultured in DMEM (Sigma-Aldrich) containing 10% FBS and 1% penicillin / streptomycin (P / S; Sigma-Aldrich) for 24 hours. The medium was then replaced with serum-free DMEM and treated with GPK, GPS, GPA, GQK, or PO peptides diluted to 0.1 μM, 1 μM, and 10 μM for 72 hours. The cells were then treated with CCK8 reagent for 1 hour, and the absorbance at 450 nm was measured using a microplate reader (TECAN). The results are shown in Figures 1-5 (Figure 1: GPK, Figure 2: GPS, Figure 3: GPA, Figure 4: GQK, Figure 5: PO). A 5% FBS (fetal bovine serum)-treated group served as a positive control (PC).

[0076] The results of Figures 1 to 5 confirm that treatment with GPK, GPS, GPA, GQK or PO peptide at concentrations of 0.1 μM, 1 μM and 10 μM significantly increased cell proliferation compared to the untreated control group, and that treatment at a concentration of 10 μM in particular had an excellent effect on activating hair papilla cell proliferation, comparable to that of the positive control group.

Claims

1. A composition for inhibiting hair loss or promoting hair growth, comprising, as an active ingredient, a peptide having the amino acid sequence Gly-Pro-Lys (GPK), the amino acid sequence Gly-Pro-Ser (GPS), the amino acid sequence Gly-Pro-Ala (GPA), the amino acid sequence Gly-Gln-Lys (GQK), or the amino acid sequence Pro-Hyp (PO), or a salt thereof.

2. The composition for inhibiting hair loss or promoting hair growth according to claim 1, wherein the peptide is a GPK, GPS, GPA, GQK or PO peptide.

3. 2. The composition for inhibiting hair loss or promoting hair growth according to claim 1, wherein the peptide or its salt is contained in the composition at a concentration of 0.001 to 100 μM.

4. The composition according to claim 1, wherein the peptide or its salt is used to treat cells at a concentration of 0.1 to 10 μM.

5. The composition of claim 4 , wherein the cells are dermal papilla cells.

6. The composition for inhibiting hair loss or promoting hair growth according to claim 1 , wherein the peptide or its salt promotes or activates the growth or proliferation of hair papilla cells.

7. The composition for inhibiting hair loss or promoting hair growth according to claim 1, wherein the composition is a pharmaceutical composition for preventing or treating hair loss.

8. 8. The composition for inhibiting hair loss or promoting hair growth according to claim 7, wherein the daily dose of the peptide or its salt is 0.0003 to 30 mg / kg (body weight).

9. The composition for inhibiting hair loss or promoting hair growth according to claim 1 , wherein the composition is a cosmetic composition.

10. 10. The composition for inhibiting hair loss or promoting hair growth according to claim 9, wherein the daily dose of the peptide or its salt is 0.0003 to 30 mg / kg (body weight).

11. The composition for inhibiting hair loss or promoting hair growth according to claim 1 , wherein the composition is a food composition.

12. 12. The composition for inhibiting hair loss or promoting hair growth according to claim 11, wherein the daily intake of the peptide or its salt is 0.0003 to 30 mg / kg (body weight).

Images